



## INFORMAZIONI PERSONALI

**LUCIA BARBIERI**

Telefono aziendale 02/55033539  
 Email aziendale lucia.barbieri@policlinico.mi.it

Sesso Femmina      Data di Nascita 31/05/1983      Nazione ITALIA

## POSIZIONE RICOPERTA

DIRIGENTE MEDICO

## ESPERIENZA PROFESSIONALE

Da Gennaio 2018 a Aprile 2021

DIRIGENTE MEDICO

ASST SANTI PAOLO E CARLO, Milano

Interventistica coronarica percutanea con esecuzione angioplastiche complesse ed occlusioni coronariche croniche (CTO). Utilizzo di aterectomia rotazionale. Valutazione di imaging e funzionalità coronarica (iFR-FFR, IVUS). Esecuzione procedure di chiusura forame ovale pervio con dispositivo Amplatzer e Gore come primo e secondo operatore. Esecuzione procedure di valvuloplastica aortica percutanea come primo e secondo operatore. Esecuzione procedure di chiusura auricola sinistra con dispositivo Watchman FLX come primo e secondo operatore. Training sostituzione valvolare aortica percutanea (TAVR) da ottobre 2019 a marzo 2020 presso Emodinamica ASST Fatebenefratelli Sacco.

Attività o Settore      CARDIOLOGICA INTERVENTISTICA, EMODINAMICA

Da Giugno 2016 a Gennaio 2018

DIRIGENTE MEDICO

OSPEDALE SANT'ANDREA Vercelli

Interventistica coronarica percutanea con esecuzione angioplastiche complesse ed occlusioni coronariche croniche (408 angioplastiche coronariche totali da primo operatore, di cui 130 angioplastiche primarie da giugno 2016 a gennaio 2018). Utilizzo di aterectomia rotazionale. Valutazione di imaging e funzionalità coronarica (iFR-FFR, IVUS, OCT). Esecuzione di procedure di chiusura forame ovale pervio come primo e secondo operatore.

Attività o Settore      CARDIOLOGICA INTERVENTISTICA, EMODINAMICA

Da Maggio 2015 a Giugno 2016

DOTTORANDA DI RICERCA con privilegi di attività assistenziale

AOU Maggiore della Carità, Novara

Svolgimento di attività clinica ed assistenziale all'interno del laboratorio di Emodinamica Universitaria (N147 angioplastiche coronariche da primo operatore di cui 21 angioplastiche primarie) e partecipazione in qualità di osservatore a procedure di sostituzione valvolare aortica percutanea (TAVR) e valvuloplastica aortica percutanea.

## ISTRUZIONE E FORMAZIONE

Da Maggio 2014 a Giugno 2018

DOTTORE DI RICERCA IN SCIENZE E BIOTECNOLOGIE MEDICHE

Università del Piemonte Orientale, Novara

Conseguimento titolo di Dottore di ricerca in scienze e biotecnologie mediche

Da Maggio 2010 a Maggio 2015

SPECIALIZZAZIONE IN MALATTIE DELL'APPARATO CARDIOVASCOLARE

SCDU Cardiologia, Università del Piemonte Orientale, Novara

Medico Chirurgo Specialista in Malattie dell'apparato cardiovascolare



## ISTRUZIONE E FORMAZIONE

Da Ottobre 2009 a Febbraio 2010 ESAME DI STATO PER ABILITAZIONE ALLA PROFESSIONE MEDICA

Ordine Provinciale dei Medici, Chirurghi e Odontoiatri di Milano

Iscrizione all'Ordine Provinciale dei Medici, Chirurghi e Odontoiatri di Milano dal 01/03/2010  
n iscrizione 41710

Da Ottobre 2003 a Luglio 2009 LAUREA MAGISTRALE IN MEDICINA, CHIRURGIA E SCIENZE DELLA SALUTE

Università del Piemonte Orientale, Novara

Dottore in Medicina e Chirurgia

## COMPETENZE PERSONALI

Lingua madre

Italiano

Altre lingue

	COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
	Ascolto	Lettura	Interazione	Produzione orale	
Inglese	C1	C1	C1	C1	C1

Livelli: A 1/2 Livello Base - B 1/2 Livello Intermedio - C 1/2 Livello Avanzato

Quadro Comune Europeo di Riferimento delle Lingue

Competenze comunicative

- PARTECIPAZIONE IN QUALITA' DI RELATORE A NUMEROSI CONGRESSI NAZIONALI/INTERNAZIONALI PRINCIPALMENTE FOCALIZZATI SU CARDIOPATIA ISCHEMICA E CARDIOLOGIA INTERVENTISTICA

- PARTECIPAZIONE IN QUALIT DI FACULTY AD EVENTI PATROCINATI DALLA SOCIET ITALIANA CARDIOLOGIA INTERVENTISTICA (GISE) E DALLA SOCIET ITALIANA DI CARDIOLOGIA (SIC):

-Congresso GISE Post-MI Clinical Cases Challenge - Ottimizzazione della terapia antiaggregante a lungo termine nel paziente colpito da MI Torino, 23-24 novembre 2017;

-GISE HIGH RISK POST PCI PATIENTS MANAGEMENT Camogli,12-13 aprile 2018;

-GISE Elderly CLINICAL CASE CHALLENGE Ottimizzazione della terapia antiaggregante nell'acuto e nel lungo termine nel paziente anziano, Milano15-16 giugno 2018;

-39 CONGRESSO NAZIONALE GISE - Milano, 16-19 Ottobre 2018;

-TRANSCATHETER INNOVATION IN PRACTICE TIP 2019 - THINKHEART WITH GISE, Roma, 3-4 maggio 2019;

-GISE Paziente con FA non valvolare sottoposto a PCI Anticoagulazione e trattamento interventistico della malattia coronarica nel paziente con FA" Milano,10-11 MAGGIO 2019;

-40 Congresso Nazionale GISE - Milano, 15-18 ottobre 2019;

-GISE LOMBARDIA: lo sguardo dei giovani verso le strategie del futuro - Milano, 08 novembre 2019

(Responsabil  
e Scientifico);

-GISE CTO 2019 - Napoli, 5-6 dicembre 2019;

-80 Congresso Nazionale della Società Italiana di Cardiologia, Roma 12 al 15 dicembre 2019;

-GISE TIP VIRTUAL 17-19 June 2020;

-81 Congresso Nazionale della Società Italiana di Cardiologia, evento virtuale 17-20 dicembre 2020;

-GISE TRANSCATHETER INNOVATION IN PRACTICE - TIP 2021, evento ibrido 16-18 giugno 2021.

Competenze organizzative e gestionali

12/2012 12/2016: CONSIGLIERE REGIONALE CON RUOLO DI SEGRETARIO-TESORIERE CONSIGLIO DIRETTIVO SIC REGIONE PIEMONTE-VALLE D'AOSTA

12/2015 12/2018: CONSIGLIO DIRETTIVO ITALIAN CARDIOLOGIST OF TOMORROW (ICOT)

08/2018 - 11/2020: BOARD MEMBER GISE YOUNG

02/2011 CURRENT: GESTIONE STUDI CLINICI NAZIONALI ED INTERNAZIONALI NELL'AMBITO DELLA CARDIOPATIA ISCHEMICA

- Sub-investigator studio CANTOS (prevenzione secondaria cardiopatia ischemica) 02/2011-05/2016

- Sub-investigator studio ODYSSEY OUTCOME (outcome cardiovascolare PCSK 9 inibitori) 04/2015-05/2016

- Sub-investigator studio REDUCE (riduzione durata terapia antiaggregante nel paziente con SCA)

03/2015-05/2016

- Principal'investigator studio ERIS (studio osservazionale utilizzo iFR-FFR nei laboratori interventistica italiani)

03/2017-01/2018

- Principal'Investigator studio ADHERE (studio osservazionale sull'aderenza terapeutica nel paziente SCA)

03/2020-in corso

- Sub-investigator studio IT-MASTER (registro osservazionale stent coronarici riassorbibili) 09/2020-in corso

Competenze professionali

DIRIGENTE MEDICO UOC CARDIOLOGIA, DISCIPLINA DI CARDIOLOGICA INTERVENTISTICA, EMODINAMICA.



Interventistica coronarica percutanea con esecuzione angioplastiche complesse ed occlusioni coronariche croniche (CTO).  
Utilizzo di aterectomia rotazionale.  
Valutazione di imaging e funzionalità coronarica (iFR-FFR, IVUS).  
Esecuzione procedure di chiusura forame ovale pervio.  
Esecuzione procedure di chiusura percutanea auricola sinistra.

Patente di guida B

ULTERIORI INFORMAZIONI

05/2013 – CURRENT:  
PUBBLICAZIONI SCIENTIFICHE  
ALLEGATI

Autore e co-autore di 96 pubblicazioni scientifiche nell'ambito della prevenzione e della cura della cardiopatia ischemica

Pubblicazioni.pdf  
Pubblicazioni congressuali.pdf

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 'Codice in materia di protezione dei dati personali'.

## Numero 40 abstract presentati a congressi nazionali ed internazionali

1. Verdoia M, Schaffer A, Barbieri L, Cassetti E, Marino P, De Luca G “Benefits from new adenosine-diphosphate antagonists as compared to clopidogrel in patients with stable angina or acute coronary syndrome: a meta-analysis of randomised trials “.Eurointervention Abstract book 2014; Euro14A-OP093
2. Barbieri L, Verdoia M, Schaffer A, Cassetti E, Marino P, Suryapranata H, De Luca G.” Uric acid levels and the risk of contrast induced nephropathy in patients with impaired renal function undergoing coronary angiography or percutaneous intervention” European Heart Journal (2014) 35 (Abstract Supplement), 132
3. Barbieri L, Verdoia M, Schaffer A, Marino P, De Luca G. “Do statins prevent contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention? A meta-analysis of 7 randomized trials” European Heart Journal (2014) 35 (Abstract Supplement), 193
4. Barbieri L, Verdoia M, Schaffer A, Cassetti E, Marino P, Suryapranata H, De Luca G.” Uric acid levels and the risk of contrast induced nephropathy in patients with impaired renal function undergoing coronary angiography or percutaneous intervention”. G ITAL CARDIOL | VOL 15 | SUPPL 1 AL N 9 2014.
5. Verdoia M, Barbieri L, Schaffer A, Di Giovine G, Cassetti E, Marino P, De Luca G “Impact of diabetes mellitus on periprocedural myocardial infarction in patients undergoing coronary stent implantation” G ITAL CARDIOL | VOL 15 | SUPPL 1 AL N 9 2014.
6. Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G. “Impact of gender on uric acid levels and its relationship with the extent of coronary artery disease: a single-centre cohort study” G ITAL CARDIOL | VOL 15 | SUPPL 1 AL N 9 2014.
7. Verdoia M, Barbieri L, Schaffer A, Marino P, De Luca G. “Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: a meta-analysis of 16 randomized trias G ITAL CARDIOL | VOL 15 | SUPPL 1 AL N 9 2014.
8. Verdoia M, Barbieri L, Schaffer A, Di Giovine G, Nardin M, Marino P, De Luca . “Impact of neutrophil to lymphocyte ratio on coronary artery disease and platelet aggregation among diabetic patients” SIC 2014
9. Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G. “Impact of gender on uric acid levels and its relationship with the extent of coronary artery disease: a single center cohort study” SIC 2014
10. Schaffer A, De Luca G, Verdoia M, Cassetti E, Barbieri L, Suryapranata H, Marino P. “Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study” SIC 2014
11. Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G. “Contrast volume to Creatinine Clearance ratio for the prediction of Contrast Induced Nephropathy in patients undergoing coronary angiography or percutaneous intervention”JACC March 17, 2015 Volume 65, Issue 10S

12. Verdoia M, Schaffer A, Barbieri L, Nardin M, Marino P, Suryapranata H, De Luca G. "Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor" Eurointervention Abstract book 2015; Euro15A-MA001
13. Barbieri L, Verdoia M, Suryapranata H, Marino P, De Luca G. "Risk and benefits of a triple antithrombotic regimen in patients undergoing percutaneous coronary stent implantation requiring chronic oral anticoagulation: a meta-analysis of 12 trials" Eurointervention Abstract book 2015; Euro15A-OP003
14. Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G. "Contrast volume to Creatinine Clearance ratio for the prediction of Contrast Induced Nephropathy in patients undergoing coronary angiography or percutaneous intervention" Eurointervention Abstract book 2015; Euro15A-P0S065
15. Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G. "Contrast volume to Creatinine Clearance ratio for the prediction of Contrast Induced Nephropathy in patients undergoing coronary angiography or percutaneous intervention" European Heart Journal (2015) 36 (Abstract Supplement), 536
16. Di Giovine G; Verdoia M, Schaffer A, Barbieri L, Marino P, Suryapranata H, De Luca G. Impact of ages on fibrinogen levels and its relationship with coronary artery disease: a single-centre study. European Heart Journal (2015) 36 (Abstract Supplement), 972
17. Barbieri L, Verdoia M, Suryapranata H, Marino P, De Luca G. Risk and benefits of a triple antithrombotic regimen in patients undergoing percutaneous coronary stent implantation requiring chronic oral anticoagulation: a meta-analysis of 12 trials. Journal of the American College of Cardiology, vol. 66; NO 15, Suppl. B; TCT-77
18. Barbieri L, Verdoia M, Nardin M, Marino P, Suryapranata H, De Luca G. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Journal of the American College of Cardiology, vol. 66; NO 15, Suppl. B; TCT-213
19. Barbieri L, Verdoia M, Pergolini P, Nardin M, Rolla R, Marino P, Bellomo G, Suryapranata H, De Luca G. Uric acid and high residual platelet reactivity in patients treated with clopidogrel or ticagrelor. G ITAL CARDIOL | VOL 16 | SUPPL 2 AL N 10 2015
20. Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G. Risk and benefits of triple therapy in patients undergoing percutaneous coronary stent implantation requiring long term oral anticoagulation: A meta analysis of 12 trials. G ITAL CARDIOL | VOL 16 | SUPPL 2 AL N 10 2015
21. Verdoia M, Barbieri L, Schaffer A, Nardin M, Marino P, Suryapranata H, De Luca G. Acetilsalicylic acid desensitization in patients with coronary artery disease: a comprehensive overview of currently available protocols. G ITAL CARDIOL | VOL 16 | SUPPL 2 AL N 10 2015

22. Verdoia M, Barbieri L, Nardin M, Schaffer A, Marino P, Suryapranata H, De Luca G. Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients. *G ITAL CARDIOL* | VOL 16 | SUPPL 2 AL N 10 2015
23. Verdoia M, Barbieri L, Schaffer A, Marino P, Suryapranata H, De Luca G. Impact of high-dose statins on vitamin d levels and platelet function in patients with coronary artery disease. *J Am Coll Cardiol*. 2016;67(13\_S):2349
24. Verdoia M., Barbieri L., Suryapranata H., De Luca G. Impact of anticoagulation strategy with bivalirudin or heparin for PCI on non-access site bleedings: a meta-analysis of randomised trials. *Eurointervention Abstract book 2016; Euro16A- OP0584*
25. Barbieri L, Verdoia M, Marino P, Rametta F, Suryapranata H, De Luca G. Impact of radial and femoral approach on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or PCI. *G Ital Cardiol 2016 Vol 17, suppl.2 P73*.
26. Verdoia M, Barbieri L, Marino P, Suryapranata H, De Luca G. Impact of pre-procedural DAPT on periprocedural myocardial infarction in patients undergoing PCI with adjunctive tirofiban. *Abstract book 2017; Euro17A- POS0130*
27. Verdoia M, Nardin M, Barbieri L, Daffara V, Marino P, De Luca G. Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. *Abstract book 2017; Euro17A- POS0129*
28. Barbieri L, Verdoia M, Rametta F, Suryapranata H, De Luca G. Impact of radial and femoral approach on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or PCI. *Abstract book 2017; Euro17A- POS0188*
29. Barbieri L, Verdoia M, Suryapranata H, Carugo S, De Luca G. Impact of 719 Trp>Arg polymorphism of KIF 6 gene on contrast induced nephropathy and modulation of statin therapy effectiveness. *G Ital Cardiol 2018 Vol 19, suppl.2 C53*
30. Barbieri L, Tumminello G, Lucreziotti S, Rametta F, Carugo S. Aterectomia rotazionale in presenza di aneurismi coronarici: metodica sicura o follia interventistica? *G Ital Cardiol 2019 Vol 20, suppl.1 P10*
31. Valli F, Lucreziotti S, Barbieri L, Persampieri S, Salerno Uriarte D, Sponzilli C, Carugo S. Accesso arterioso radiale distale: nuova frontiera per la cardiologia interventistica? *G Ital Cardiol 2019 Vol 20, suppl.1 P10*
32. Barbieri L, Tumminello G, Lucreziotti S, Rametta F, Carugo S. Aterectomia rotazionale in presenza di aneurismi coronarici: metodica sicura o follia interventistica? *G Ital Cardiol 2019 Vol 20, suppl.1 P12*
33. Barbieri L, Tumminello G, Lucreziotti S, Rametta F, Carugo S. Rotational atherectomy and coronary aneurysms: a safe tool or interventional madness? Results from a multicentre case series. *Eurointervention Suppl Vol. 16, 2020 e453*.
34. Barbieri L, Ferrante G, Sponzilli C, Lucreziotti S, Carugo S. Predictors of Mortality and long term outcome in patients with anterior STEMI: results from a single center study. *Eurointervention Suppl Vol. 16, 2020 e455*.

35. Bollati M, Quadri G, Trabattoni D, Gili S, Cerrato E, Regazzoli D, Pivato CA, Tomassini F, Barbieri L, Carugo S, dall'Ara G, Galvani M, Reimers B, Pancioli C, Varbella F, Marangoni E. Covid-19, ACS and phase 2: a picture after the italian outbreak. *P30 G Ital Cardiol* 2020;21(10 Suppl. 1):e4-e21.
36. Tumminello G, Barbieri L, Lucreziotti S, Gentile D, Conconi B, Carlà M, Centola M, Mafrici A, Carugo S. Impatto del Covid-19 sulla gestione del paziente con infarto miocardico acuto: seconda giovinezza per la fibrinolisi o tempo per una gestione centralizzata? Esperienza di un centro hub. *P31 G Ital Cardiol* 2020;21(10 Suppl. 1):e4-e21.
37. Barbieri L, Tumminello G, Lucreziotti S, Gentile D, Centola M, Conconi B, Carlà M, Salerno-Uriarte D, Panzacchi G, Mafrici A, Carugo S. Mortality in STEMI patients during the Covid era: has the pandemic changed our clinical practice? *P32 G Ital Cardiol* 2020;21(10 Suppl. 1):e4-e21.
38. Lucreziotti S, Persampieri S, Barbieri L, Gentile D, Salerno-Uriarte D, Valli F, sabatelli L, Panzacchi G, Centola M, Sponzilli C, carugo S. Incidence of arm hematoma after percutaneous coronary intervention. A comparison of distal transradial access and conventional transradial access in a randomized clinical trial. *P41 G Ital Cardiol* 2020;21(10 Suppl. 1):e4-e18.
39. Tumminello G, Barbieri L, Lucreziotti S, Conconi B, Gentile D, Carlà M, Centola M, Mafrici A, Carugo S. Impatto del Covid-19 sulla gestione del paziente con infarto miocardico acuto: seconda giovinezza per la fibrinolisi o tempo per una gestione centralizzata? Esperienza di un centro hub A296: *G Ital Cardiol* 2020;21(12 Suppl. 2):e3-e177.
40. Barbieri L, Trabattoni D, Stefanini G, Vizzardi E, Tumminello G, Assanelli E, Adamo M, Pivato CA, Provenzale G, Gentile D, Metra M, Carugo S. Impact of RAAS inhibitors on clinical outcome and mortality in STEMI patients during the Covid era: a multicentre observational study A242: *G Ital Cardiol* 2020;21(12 Suppl. 2):e3-e177.

## Publicazioni

1. Cereda A, Conca C, Barbieri L, Ferrante G, Tumminello G, Lucreziotti S, Guazzi M, Mafri A. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: Serendipity or atypical causal relationship? *Anatol J Cardiol* 2021 Jul;25(7):522-523.
2. Pagnesi M, Inciardi RM, Lombardi CM, Agostoni P, Ameri P, Barbieri L, Bellasi A, Camporotondo R, Canale C, Carubelli V, Carugo S, Catagnano F, Dalla Vecchia LA, Danzi GB, Di Pasquale M, Gaudenzi M, Giovinazzo S, Gnechi M, Guazzi M, Iorio A, La Rovere MT, Leonardi S, Mapelli M, Margonato D, Merlo M, Monzo L, Mortara A, Nuzzi V, Piepoli M, Porto I, Pozzi A, Sarullo F, Sinagra G, Tedino C, Tomasoni D, Volterrani M, Zaccone G, Senni M, Metra M. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study. *Int J Infect Dis.* 2021 Jul;108:270-273.
3. Verdoia M, Barbieri L, De Luca G. Antiplatelet therapy in ACS elderly patients: Another piece of this intriguing puzzle. *Int J Cardiol.* 2021 Jul 1;334:28-29.
4. D'Ascenzo F, De Filippo O, Borin A, Barbieri L, Adamo M, Morici N, Truffa Giachet A, Iannaccone M, Crimi G, Gaido L, Bocchino PP, Pivato CA, Campo G, Trabattoni D, Chieffo A, Gaibazzi N, Angelini F, Rubboli A, Rognoni A, Musumeci G, Ugo F, Gili S, Cortese B, Vadalà P, Dusi V, Gallone G, Patti G, De Ferrari GM. Impact of COVID-19 pandemic and infection on in hospital survival for patients presenting with acute coronary syndromes: A multicenter registry. *Int J Cardiol* 2021 Jun 1;332:227-234.
5. Kedhi E, Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, Lalmand J, van der Schaaf RJ, Koh TH, Timmermans Sr P, Dilling-Boer D, Veenstra LF, Van' T Hof AW, Lee SW, Roolvink V, Ligtenberg E, Postma S, Kolkman EJ, Brouwer MA, Dudek D, De Luca G. Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial. *Atherosclerosis* 2021 Feb 16;321:39-44.
6. Tumminello G, Barbieri L, Toriello F, Lucreziotti S, Carlà M, Conconi B, Mafri A, Carugo S. Influence of different COVID-19 pandemic phases on STEMI: Experience from an Italian Hub centre. *Cardiovasc Revasc Med.* 2021 Jul 7;S1553-8389(21)00514-5.
7. Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, Rasoul S, Liew HB, Polad J, Ahmad WAW, Zambahari R, Lalmand J, van der Schaaf RJ, Koh TH, Timmermans Sr P, Dilling-Boer D, Veenstra LF, Van't Hof AWJ, Lee SWL, Roolvink V, Ligtenberg E, Postma S, Kolkman EJJ, Brouwer MA, Kedhi E, De Luca G. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial. *J Thromb Thrombolysis* 2021 Apr 13. doi: 10.1007/s11239-021-02439-x.
8. Podestà MA, Valli F, Galassi A, Cassia MA, Ciceri P, Barbieri L, Carugo S, Cozzolino M. COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors. *Blood Purif* 2021 Mar 22;1-10.



9. Barbieri L, Galli F, Conconi B, Gregorini T, Lucreziotti S, Mafrici A, Pravettoni G, Sommaruga M, Carugo S. Takotsubo syndrome in COVID-19 era: Is psychological distress the key? *J Psychosom Res* 2020 Nov 15;140:110297.
10. Barbieri L, Tumminello G, Lucreziotti S, Gentile D, Centola M, Conconi B, Carlà M, Mafrici A, Carugo S. Mortality in STEMI patients during the COVID era: Has the pandemic changed our clinical practice? *Cardiovasc Revasc Med* 2020 Sep 10;S1553-8389(20)30563-7.
11. Tomasoni D, Inciardi RM, Lombardi CM et al. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. *Eur J Heart Fail* 2020 Nov 12. doi: 10.1002/ejhf.2052. Online ahead of print.
12. Cammann VL, Szawan KA, D'Ascenzo F, Gili S, Dreiding S, Würdinger M, Manka R, Stähli BE, Holy EW, Siegrist P, Jakob P, Meyer P, Iannaccone M, Di Simone E, Secco GG, Saccocci M, Bettari L, Ielasi A, Tespili M, Quadri G, Varbella F, Raposeiras-Roubin S, Abu-Assi E, Mancone M, Sardella G, Infusino F, Fedele F, Patti G, Mennuni M, Rognoni A, Bollati M, Olivotti L, Cordone S, Carugo S, Barbieri L, Gaido L, Giammaria M, Gambino A, D'Amico M, Galluzzo A, Ugo F, Trabattoni D, De Filippo O, De Ferrari GM, Vecchione C, Citro R, Ghadri JR, Templin C. Outcomes of acute coronary syndromes in coronavirus disease 2019. *Clin Res Cardiol* 2020 Sep 19;1-4.
13. Lucreziotti S, Persampieri S, Barbieri L, Carugo S. Sliding doors: Sternal dehiscence on stage. *Gazzetta Medica Italiana Archivio per le Scienze Mediche* October;179(10):604-5.
14. Tumminello G, Barbieri L, Lucreziotti S, Gentile D, Conconi B, Centola M, Mafrici A, Carugo S. Impact of COVID-19 on STEMI: Second youth for fibrinolysis or time to centralized approach? *Int J Cardiol Heart Vasc* 2020 Jul 23;30:100600.
15. Persampieri S, Lucreziotti S, Salerno-Uriarte D, Barbieri L, Sponzilli C, Valli F, Centola M, Castini D, Carugo S. Predictors of procedural and clinical outcome in rotational atherectomy: Analysis of a single center registry. *Minerva Cardioangiol* 2020 Apr;68(2):126-133.
16. Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, Metra M, Curello S, Maffeo D, Pero G, Cacucci M, Assanelli E, Bellini B, Russo F, Ielasi A, Tespili M, Danzi GB, Vandoni P, Bollati M, Barbieri L, Oreglia J, Lettieri C, Cremonesi A, Carugo S, Reimers B, Condorelli G, Chieffo A. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes. *Circulation*. 2020 Jun 23;141(25):2113-2116.
17. Lucreziotti S, Belletti S, Toriello F, Barbieri L, Antona C, Carugo S. Acute coronary syndrome in a patient with congenital atresia of the left main coronary artery, *Sindrome coronarica acuta in un paziente con atresia congenita del tronco comune della coronaria sinistra*. *G Ital Cardiol (Rome)* 2020 Apr;21(4):315-316.
18. Nardin M, Verdoia M, Barbieri L, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of metabolic syndrome on mean platelet volume and its relationship with coronary artery disease. *Platelets*. 2019;30(5):615-623.

19. De Luca L, Temporelli PL, Riccio C, Gonzini L, Marinacci L, tartaglione SN, Costa P, Scherillo M, Senni M, Colivicchi F, Gulizia MM. START Investigators. Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study. *Eur Heart J Qual Care Clin Outcomes*. 2019 Oct 1;5(4):334-342.
20. Mattesini A, Masiero G, Barbieri L, Vizzari G, Tarantino F, La Manna A, Mauro C, Limbruno U, Rigattieri S, Castiglioni B, Marchese A, Musumeci G, Tarantini G.[Dyslipidemia management for secondary prevention in cardiovascular disease: from guidelines to clinical practice]. *G Ital Cardiol (Rome)*. 2019 Sep;20(9 Suppl 1):44S-49S.
21. Verdoia M, Erbetta R, Sagazio E, Barbieri L, Negro F, Suryapranata H, Kedhi E, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of increasing dose of intracoronary adenosine on peak hyperemia duration during fractional flow reserve assessment. *Int J Cardiol*. 2019 Jun 1;284:16-21.
22. Verdoia M, Pergolini P, Nardin M, Rolla R, Barbieri L, Marino P, Carriero A, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group. Prevalence and predictors of high-on-treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation. *J Cardiol*. 2019 Mar;73(3):198-203.
23. Barbieri L, Verdoia M, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention. *Int J Cardiol*. 2019 Jan 15;275:48-52.
24. Verdoia M, Barbieri L, Kedhi E, Suryapranata H, De Luca G. Percutaneous versus surgical revascularization for left main or multi vessel coronary artery disease: results from a large-scale Meta analysis in the era of drug-eluting stents. *Angiology*. 2018 Oct;69(9):812-824.
25. Verdoia M, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Impact of long term dual antiplatelet therapy on immature platelet count and platelet reactivity. *Angiology*. 2018 Jul;69(6):490-496.
26. Verdoia M, Pergolini P, Barbieri L, Rolla R, Nardin M, Negro F, Suryapranata H, De Luca G. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban. *Thromb Res*. 2018 Apr;164:17-23.
27. Verdoia M, Barbieri L, Nardin M, Suryapranata H, De Luca G. Dual versus single antiplatelet regimen with or without anticoagulation in transcatheter aortic valve replacement: indirect comparison and meta-analysis. *Rev Esp Cardiol (Engl Ed)*. 2018 Apr;71(4):257-266.
28. Nardin M, Verdoia M, Pergolini P, Rolla R, Barbieri L, Marino P, Bellomo G, Kedhi E, Suryapranata H, Carriero A, De Luca G. Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. *Pharmacol Res*. 2018 Mar;129:27-33.

29. De Luca G, Verdoia M, Barbieri L, Marino P, Suryapranata H. Resting Pd/Pa and haemodynamic relevance of coronary stenosis as evaluate by fractional flow reserve. *Coron Artery Dis.* 2018 Mar;29(2):138-144.
30. Nardin M, Verdoia M, Barbieri L, Schaffer A, Suryapranata H, De Luca G. Radial vs femoral approach in acute coronary syndrome: a meta-analysis of randomized trials. *Curr Vasc Pharmacol* 2017;16(1):79-92.
31. Rognoni A, Cavallino C, Mennuni MG, Barbieri L, Rosso R, Rametta F, Nardi F, Lupi A, Bongo AS. Out-of-hospital cardiac arrest: always coronary angiography? *Expert Rev Cardiovasc Ther.* 2017 Nov;15(11):847-851.
32. Verdoia M, Barbieri L, Parodi G, Bellandi B, Schaffer A, Suryapranata H, De Luca G. Impact of anticoagulation strategy with bivalirudin or heparin on nonaccess site bleeding in percutaneous coronary interventions: A meta-analysis of randomized trials. *Catheter Cardiovasc Interv.* 2017 Oct 1;90(4):553-565.
33. Barbieri L, Verdoia M, Nardin M, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Gender Difference in the Risk of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention. *Angiology.* 2017 Jul;68(6):542-546.
34. Verdoia M, Pergolini P, Rolla R, Nardin M, Schaffer A, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. *Thromb Res.* 2017 Feb;150:90-95.
35. Barbieri L, Verdoia M, Schaffer A, Suryapranata H, De Luca G. Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies. *Cardiovasc Drugs Ther.* 2016 Dec;30(6):611-622.
36. Verdoia M, Pergolini P, Rolla R, Sartori C, Nardin M, Schaffer A, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, Luca GD; Novara Atherosclerosis Study Group (NAS). Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. *Platelets.* 2016 Sep;27(6):576-82.
37. Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. *Cardiovasc Ther.* 2016 Aug;34(4):209-15.
38. Camaro C, Damen SA, Brouwer MA, Kedhi E, Lee SW, Verdoia M, Barbieri L, Rognoni A, van T Hof AW, Ligtenberg E, de Boer MJ, Suryapranata H, De Luca G. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. *Am Heart J.* 2016 Aug;178:37-44.

39. Verdoia M, Schaffer A, Barbieri L, Suryapranata H, De Luca G. Bivalirudin Versus Unfractionated Heparin in Acute Coronary Syndromes: An Updated Meta-analysis of Randomized Trials. *Rev Esp Cardiol (Engl Ed)*. 2016 Aug;69(8):732-45.
40. Verdoia M, Pergolini P, Nardin M, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. *J Thromb Thrombolysis*. 2016 Aug;42(2):245-53.
41. Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Bellomo G, Marino P, Suryapranata H, De Luca G. Impact of neutrophil-to-lymphocyte ratio on periprocedural myocardial infarction in patients undergoing non-urgent percutaneous coronary revascularisation. *Neth Heart J*. 2016 Jul;24(7-8):462-74.
42. Nardin M, Verdoia M, Schaffer A, Barbieri L, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography. *Atherosclerosis*. 2016 Jul;250:114-21.
43. Nardin M, Verdoia M, Sartori C, Pergolini P, Rolla R, Barbieri L, Schaffer A, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients. *Thromb Res*. 2016 Jul;143:45-9.
44. Nardin M, Verdoia M, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. *Nutr Metab Cardiovasc Dis*. 2016 Jul;26(7):567-74.
45. Verdoia M, Barbieri L, Schaffer A, Bellomo G, Marino P, De Luca G; Novara Atherosclerosis Study (NAS) group. Impact of renal function on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study. *Thromb Res*. 2016 May;141:139-44.
46. Schaffer A, Verdoia M, Barbieri L, Cassetti E, Suryapranata H, De Luca G. Impact of Diabetes on Homocysteine Levels and Its Relationship with Coronary Artery Disease: A Single-Centre Cohort Study. *Ann Nutr Metab*. 2016;68(3):180-8.
47. Verdoia M, Barbieri L, Schaffer A, Nardin M, Suryapranata H, De Luca G. Acetylsalicylic acid desensitization in patients with coronary artery disease: A comprehensive overview of currently available protocols. *Vascul Pharmacol*. 2016 May;80:43-9.
48. Verdoia M, Sartori C, Pergolini P, Nardin M, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes. *J Thromb Thrombolysis*. 2016 May;41(4):663-70.
49. Barbieri L, Verdoia M, Pergolini P, Nardin M, Rolla R, Marino P, Bellomo G, Suryapranata H, De Luca G. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor. *Nutr Metab Cardiovasc Dis*. 2016 Apr;26(4):352-8.

50. Barbieri L, Pergolini P, Verdoia M, Rolla R, Nardin M, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. *Vascul Pharmacol*. 2016 Apr;79:11-5.
51. Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Daffara V, Marino P, Bellomo G, Suryapranata H, Luca GD; Novara Atherosclerosis Study Group (NAS). Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy. *Cardiovasc Drugs Ther*. 2016 Apr;30(2):143-50.
52. Verdoia M, Schaffer A, Barbieri L, Montalescot G, Collet JP, Colombo A, Suryapranata H, Luca G. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials. *Angiology*. 2016 Mar;67(3):224-38.
53. Verdoia M, Barbieri L, Suryapranata H, De Luca G. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. *Platelets*. 2016;27(2):93-104.
54. Verdoia M, Sartori C, Pergolini P, Nardin M, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. *Vascul Pharmacol*. 2016 Feb;77:48-53.
55. Verdoia M, Pergolini P, Rolla R, Nardin M, Schaffer A, Barbieri L, Marino P, Bellomo G, Suryapranata H, De Luca G. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. *J Thromb Haemost*. 2016 Jan;14(1):57-64.
56. Verdoia M, Barbieri L, Giovine GD, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Neutrophil to Lymphocyte Ratio and the Extent of Coronary Artery Disease: Results From a Large Cohort Study. *Angiology*. 2016 Jan;67(1):75-82.
57. Verdoia M, Nardin M, Sartori C, Pergolini P, Rolla R, Barbieri L, Marino P, Bellomo G, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy. *Atherosclerosis*. 2015 Dec;243(2):389-94.
58. Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy. *Cardiovasc Drugs Ther*. 2015 Oct;29(5):443-450.
59. Nardin M, Verdoia M, Sartori C, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Body Mass Index and platelet reactivity during dual antiplatelet therapy with clopidogrel or ticagrelor. *J Cardiovasc Pharmacol*. 2015 Oct;66(4):364-70.
60. Verdoia M, Schaffer A, Barbieri L, Aimaretti G, Marino P, Sinigaglia F, Suryapranata H, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS). Impact of diabetes

- on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease. *Diabetes Metab.* 2015 Sep;41(4):304-11.
61. Di Giovine G, Verdoia M, Barbieri L, Schaffer A, Aimaretti G, Bellomo G, Marino P, Suryapranata H, Sinigaglia F, De Luca G; Novara Atherosclerosis Study (NAS) group. Impact of diabetes on fibrinogen levels and its relationship with platelet reactivity and coronary artery disease: A single-centre study. *Diabetes Res Clin Pract.* 2015 May 18.
  62. Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. *Expert Opin Pharmacother.* 2015 Aug;16(12):1739-47.
  63. Verdoia M, Schaffer A, Pergolini P, Rolla R, Barbieri L, Bellomo G, Sinigaglia F, Marino P, Suryapranata H, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS). Homocysteine levels influence platelet reactivity in coronary artery disease patients treated with acetylsalicylic acid. *J Cardiovasc Pharmacol.* 2015 Jul;66(1):35-40.
  64. Schaffer A, Verdoia M, Casseti E, Barbieri L, Perrone-Filardi P, Marino P, De Luca G. Impact of red blood cells count on the relationship between high density lipoproteins and the prevalence and extent of coronary artery disease: a single centre study. *J Thromb Thrombolysis.* 2015 Jul;40(1):69.
  65. Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G; of the Novara Atherosclerosis Study Group (NAS). Glycosylated hemoglobin and the risk of periprocedural myocardial infarction in non-diabetic patients. *J Diabetes Complications.* 2015 May-Jun;29(4):517-22.
  66. Verdoia M, Schaffer A, Barbieri L, Suryapranata H, De Luca G. Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: A meta-analysis of 22 randomized trials. *Thromb Res.* 2015 May;135(5):902-15.
  67. Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. *Nutr Metab Cardiovasc Dis.* 2015 May;25(5):464-70.
  68. Barbieri L, Verdoia M, Schaffer A, Niccoli G, Perrone-Filardi P, Bellomo G, Marino P, Suryapranata H, De Luca G. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study. *Angiology.* 2015 Apr;66(4):333-8.
  69. Verdoia M, Schaffer A, Barbieri L, Casseti E, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting. *J Cardiovasc Med (Hagerstown).* 2015 Feb;16(2):100-5.
  70. Barbieri L, Verdoia M, Schaffer A, Marino P, De Luca G. [Two catheters for one coronary perforation]. *G Ital Cardiol (Rome).* 2015 Feb;16(2):112-5.
  71. Barbieri L, Verdoia M, Schaffer A, Casseti E, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Uric acid levels and the risk of Contrast

- Induced Nephropathy in patients undergoing coronary angiography or PCI. *Nutr Metab Cardiovasc Dis.* 2015 Feb;25(2):181-6.
72. Verdoia M, Schaffer A, Barbieri L, Bellomo G, Marino P, Sinigaglia F, Suryapranata H, De Luca G; Novara Atherosclerosis Study (NAS) group. Impact of age on mean platelet volume and its relationship with coronary artery disease: a single-centre cohort study. *Exp Gerontol.* 2015 Feb;62:32-6.
  73. Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group. Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention. *Eur J Prev Cardiol.* 2016 Jun;23(9):931-7.
  74. Verdoia M, Barbieri L, Schaffer A, Cassetti E, Marino P, Bellomo G, Sinigaglia F, De Luca G; Novara Atherosclerosis Study Group (NAS). Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization. *Heart Vessels.* 2015 Jan;30(1):20-7.
  75. Verdoia M, Barbieri L, Schaffer A, Cassetti E, Di Giovine G, Nardin M, Bellomo G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Effect of diabetes mellitus on periprocedural myocardial infarction in patients undergoing coronary stent implantation. *Diabetes Metab Res Rev.* 2015 Jan;31(1):85-92.
  76. Barbieri L, Verdoia M, Schaffer A, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study. *Atherosclerosis.* 2015 Jul;241(1):241-8.
  77. Verdoia M, Secco GG, Cassetti E, Schaffer A, Barbieri L, Perrone-Filardi P, Marino P, Suryapranata H, Sinigaglia F, De Luca G. Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty. *Blood Coagul Fibrinolysis.* 2014 Mar;25(2):107-13.
  78. Verdoia M, Cassetti E, Schaffer A, Barbieri L, Giovine GD, Nardin M, Marino P, Sinigaglia F, Luca GD; Novara Atherosclerosis Study Group (NAS). Relationship between glycoprotein IIIa platelet receptor gene polymorphism and coronary artery disease. *Angiology.* 2015 Jan;66(1):79-85.
  79. Schaffer A, Cassetti E, Di Iovine MG, Barbieri L, Rognoni A, Secco G.G, Lazzero M, Bongo A.S, Porto I, Lupi A. Computed tomography imaging of the coronary arteries: State of the art applications and recent patents. *Recent Patents on Medical Imaging.* 2014;4(1):22-30.
  80. Barbieri L, Rognoni A, Secco G.G, Cassetti E, Schaffer A, Di Giovine G, Lazzero M, Bongo A.S, Marino P, De Luca G, Porto I, Lupi A. Coronary intravascular ultrasound (IVUS): Contemporary applications and bases for the future. *Recent Patents on Medical Imaging.* 2014;4(1):6-15.
  81. Nardi F, Prando M, Lazzero M, Colonna P, Michelotto E, Andreini D, Casolo G.C, Barbieri L, Cassetti E, Schaffer A, Bongo A.S, Rognoni A. Cardiovascular imaging in

- thromboembolic risk stratification for atrial fibrillation: Recent patents and current practice. *Recent Patents on Medical Imaging*. 2014;4(1):41-53.
82. Barbieri L, Verdoia M, Schaffer A, Cassetti E, Di Giovine G, Marino P, Suryapranata H, De Luca G. Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention. *Diabetes Res Clin Pract*. 2014 Dec;106(3):458-64.
  83. Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G. The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials. *J Thromb Thrombolysis*. 2014 Nov;38(4):493-502.
  84. Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, Luca GD; on behalf of the Novara Atherosclerosis Study Group (NAS). "High-density Lipoproteins and Coronary Artery disease: A Single-center Cohort Study". *Angiology*. 2014 Sep;65(8):696-702.
  85. Verdoia M, Schaffer A, Barbieri L, Sinigaglia F, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS). Eosinophils count and periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions. *Atherosclerosis*. 2014 Sep;236(1):169-74.
  86. Verdoia M, Secco GG, Barbieri L; Cassetti E, Schaffer A, Marino P, Suryapranata H, De Luca G on behalf of the Novara Atherosclerosis Study Group. "Platelet P1A1/P1A2 polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI". *Platelets*. 2014;25(5):367-72.
  87. Verdoia M, Schaffer A, Sartori C, Barbieri L, Cassetti E, Marino P, Galasso G, De Luca G. Vitamin D deficiency is independently associated with the extent of coronary artery disease. *Eur J Clin Invest*. 2014 Jul;44(7):634-42.
  88. Verdoia M, Schaffer A, Cassetti E, Barbieri L, Di Ruocco MV, Perrone-Filardi P, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Glycosylated hemoglobin and coronary artery disease in patients without diabetes mellitus. *Am J Prev Med*. 2014 Jul;47(1):9-16.
  89. Verdoia M, Barbieri L, Schaffer A, Cassetti E, Nardin M, Bellomo G, Aimaretti G, Marino P, Sinigaglia F, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: a single-centre cohort study. *Metabolism*. 2014 May;63(5):640-6.
  90. Verdoia M, Schaffer A, Barbieri L, Cassetti E, Nardin M, Bellomo G, Marino P, Sinigaglia F, De Luca G; Novara Atherosclerosis Study (NAS) group. Diabetes, glucose control and mean platelet volume: a single-centre cohort study. *Diabetes Res Clin Pract*. 2014 May;104(2):288-94.
  91. Verdoia M, Schaffer A, Cassetti E, Barbieri L, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). MTHFR polymorphism and risk of periprocedural myocardial infarction after coronary stenting. *Nutr Metab Cardiovasc Dis*. 2014 May;24(5):532-7.



92. Verdoia M, Schaffer A, Barbieri L, Cassetti E, Piccolo R, Galasso G, Marino P, Sinigaglia F, De Luca G. Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. *J Cardiovasc Pharmacol*. 2014 Apr;63(4):339-50.
93. Verdoia M, Barbieri L, Schaffer A, Cassetti E, Di Giovine G, Bellomo G, Marino P, Sinigaglia F, De Luca G. "Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention". *J Thromb Thrombolysis*. 2014 Apr;37(3):345-52.
94. Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, De Luca G; Novara Atherosclerosis Study Group (NAS). Uric acid and risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. *Diabetes Metab Res Rev*. 2014 May;30(4):297-304.
95. Verdoia M, Camaro C, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G. Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty. *Atherosclerosis*. 2013 May;228(1):136-41.
96. Rognoni A, Barbieri L, Cavallino C, Bacchini S, Veia A, Degiovanni A, Rametta F, Nardi F, Lazzeri M, Lupi A, Bongo AS. Ranolazine: effects on ischemic heart. *Recent Pat Cardiovasc Drug Discov*. 2013 Dec;8(3):197-203. Review.